The Only Industry Dedicated Complement Therapeutics Meeting
Optimize Novel Pathway Targeting, Assay Validation & Clinical Translation to Drive Complement Inhibition Development.
Join 150+ senior level complement experts from pharma, biotech and leading research institutions who are all working towards the same goal … to achieve clinical approval of effective complement inhibitors in rare and common disease indications.
This leading Complement-based Drug Development conference provides a platform to share cutting edge data, understand the current clinical landscape and gain feedback from the industry on the right pathways and indications to target to ensure clinical success.
As the number of companies pursuing complement-based therapeutics is growing with rapidly expanding pipelines, the field is set to explode! The time has come to seize the therapeutic opportunity of complement inhibition, not only in rare disorders but also for more common disease indications. This meeting highlights the clinical developments of druggable complement targets from C5 and beyond.
Don’t miss out on your chance to network with the industry leaders, explore methods to improve clinical trial design to manage potential safety risks and identify translatable biomarkers to ensure successful drug approval.
With Novartis, Achillion, Roche, Sanofi & many more in the mix, will you be there too?
"This was a well-balanced mix of speakers representing early and late drug development efforts and approaches that have worked and ones that have failed, we often only hear the success stories, but one can learn maybe even more from the failures."
"The Complement-based Drug Development regrouped the majority of the key players of the Pharmaceutical Industry in the complement field. It is priceless to be able to interact with each other at this level of Science"
"As an academic researcher, I had a rare and valuable experience to be exposed to the way industry leaders approach some challenging topics, assess various sources of data and take scientific and business decisions. I learned a lot and my perspective has been enriched"